Change Country
Welcome to Belgium
Please read the important information below before continuing to our website

The UCITS ETFs listed on this website are funds under both Amundi ETF and Lyxor ETF denomination.

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 

If you are an investor in the United Kingdom, please go to  

If you are an investor in the Netherlands, please go to  

If you are an investor in Italy, please go to  

If you are an investor in Spain, please go to  

If you are an investor in Austria, please go to  

If you are an investor in Germany, please go to   

If you are an investor in Singapore, please go to  

If you are an investor in Switzerland, please go to  

If you are an investor in Belgium, please go to  

If you are an investor in Poland, please go to 

If you are an investor in Norway, please go to

If you are an investor in Denmark, please go to

If you are an investor in Luxembourg, please go to

If you are an investor in Sweden, please go to

If you are an investor in Finland, please go to

The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 91-93, boulevard Pasteur, 75015 Paris -France.

The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:

(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.

In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 

Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.

This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.

The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.

Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 

Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 

By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Belgium.

We have a new home

Banner Amundi

Read more
20 Apr 2020

How Artificial Intelligence is reshaping our economy

global green

In our latest guest blog, futurist Martin Ford discusses the latest developments of the index underlying Lyxor’s Robotics and AI ETF launched in 2018. He believes AI has huge potential to transform all sectors of our economy, and that this is well reflected in the index holdings.

Martin Ford is a futurist focusing on the impact of artificial intelligence and robotics on society and the economy. He is author of the book “Rise of the Robots: Technology and the Threat of a Jobless Future”, and acts as a consultant to Société Générale, the index designer.

The Rise of the Robots index

The SG Rise of the Robots Index has a broad focus on identifying publicly-traded companies which are likely to benefit from the emerging revolution in AI and robotics. While the index includes a comprehensive selection of companies innovating in areas directly related to AI and automation, the strategy is really built on the belief that artificial intelligence is rapidly evolving into a kind of utility—a force poised to scale across and transform the entire global economy. So, the index includes companies in a variety of industries outside the tech sector which are able to leverage these technologies in their business models.

AI – a force poised to transform virtually all sectors

There is growing evidence that artificial intelligence is rapidly becoming a systemic technology. For example, in July 2019, Microsoft invested a billion dollars in the San Francisco-based research organisation OpenAI. OpenAI is focused on building truly advanced, or human-level, AI, an endeavor that is likely to take decades.

In the meantime, OpenAI’s research will spawn many practical applications for Microsoft both in its operations and in its cloud computing division, Azure. The integration of powerful AI capability into cloud computing platforms, and the intense competition is this area between the major players Amazon, Microsoft, and Google, is transforming the cloud into the most important conduit for delivering artificial intelligence to virtually every industry sector.

A hybrid index built to evolve with the times

At the end of each calendar year, we update the universe of companies available for inclusion in the Rise of the Robots index. The universe includes stocks we believe are good candidates for index inclusion based on factors such as company strategy and technical focus on AI or robotics. Companies that make it into the index itself are selected algorithmically based on several financial measures including R&D expenditure on net sales, return on invested capital, and 3-year sales growth. Therefore, the index is managed according to a hybrid system where we combine annual judgment on eligible stocks with a purely systematic approach to selecting stocks from that eligible universe.  

Index additions: from cloud computing and 3D printing to remote healthcare and gene sequencing

Companies added in the information technology sector this year include, for example, Cloudera, based in Palo Alto, California.  Cloudera offers a range of software and services geared towards enterprise cloud computing. The company has a strong focus on tools that enable its clients to leverage cloud resources in machine learning and AI applications. 

UK based AVEVA Group, Plc is a leading provider of industrial and engineering software. The company is integrating artificial intelligence capability to enhance productivity for a range of sectors, including chemicals, food processing, life sciences, oil and gas and mining. Elastic, N.V. founded in the Netherlands and now headquartered in Silicon Valley, builds AI-enabled software that enables data search and retrieval.

Companies added in the healthcare and life science sectors include Pennsylvania-based BioTelemetry, Inc, which produces smart devices currently used to remotely monitor over a million cardiology patients. The company is in a strong position to leverage AI to extract important insights from this data.

Gene-sequencing company Illumina, Inc. headquartered in San Diego, CA, is deploying AI and machine learning to search for mutations in the genomes of patients with genetic diseases—an innovation that could eventually lead to treatments. Illumina’s gene sequencing technology was used in January in one of the first attempts to characterise the genome of the coronavirus, which was at the time making its first appearance in Wuhan, China.  Mountain View, CA-based Omnicell Inc makes pharmacy robots designed to fully automate the preparation of medications in hospitals.

Other additions include the Belgian company Materialize NV, which is a global leader in 3D printing, and GEA Group AG, based in Düsseldorf, Germany, that specialises in advanced automation for the food and beverage industries. 

27 new eligible constituents for 2020

In all, the 2020 universe update, which reflects changes in the status and strategies of companies, as well as corporate takeovers and IPOs that occurred during the year, adds 27 new eligible constituents.  The total number of stocks now in the universe is now 248. Of these, 150 are selected systematically for inclusion in the index.

We believe this selection of relevant stocks results in an investment vehicle uniquely positioned to effectively capture the enormous value likely to be generated through the utilisation of AI and robotics across nearly all economic sectors. 

The view from Lyxor

Our $130m+ Lyxor Robotics & AI UCITS ETF is the only ETF of its kind combining human expertise, big data, and fundamental weighting favouring businesses with a proven track record of increasing sales and spending on R&D.1

Unlike many similar available ETFs, the underlying index is designed to capture the full opportunity set of robotics, automation and AI, across sectors. Over 40 of its holdings are unique and not found in peer indices.1

Over a 1-year and 5-year period, the index has outperformed similar indices tracked by comparable ETFs in the European market, while the fund itself has outperformed its ETF peers since its inception in 2018. A large amount of this outperformance came from these unique stocks not found in peer funds.1

Find out more about the ‘Rise of the Robots’ index underlying our ETF

1Source: Lyxor International Asset Management, as of 09/02/2020. Statements about Lyxor credentials vs. peers are based on the European UCITS ETF market only. Peer ETF group selected by Lyxor based on relevant target exposures in the areas of robotics, automation and artificial intelligence. Past performance is not a reliable indicator of future returns.

This article is for informative purposes only, and should not be taken as investment advice. Lyxor ETF does not in any way endorse or promote the companies mentioned in this article. The opinions expressed by Martin Ford are his own, and do not necessarily reflect the views of Lyxor International Asset Management or Societe Generale. Martin Ford is a futurist focusing on the impact of artificial intelligence and robotics on society and the economy. He is author of the book “Rise of the Robots: Technology and the Threat of a Jobless Future”, and acts as a consultant to Société Générale, the index designer. Capital at risk. Please read our Risk Warning below.

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on, and upon request to

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website

Conflicts of interest 

This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin